Amiselimod hydrochloride

Research use only, not for human use.

A novel prodrug S1P receptor modulator lacking S1P3 receptor agonism to avoid bradycardia associated with fingolimod and other S1P receptor modulators.

A novel prodrug S1P receptor modulator lacking S1P3 receptor agonism to avoid bradycardia associated with fingolimod and other S1P receptor modulators; the selectivity of the active metabolite amiselimod phosphate (Amiselimod-P) shows potent selectivity for S1P1 and high selectivity for S1P5 receptors, with minimal agonist activity for S1P4 and no distinct agonist activity for S1P2 or S1P3 receptors and approximately five-fold weaker GIRK activation than fingolimod-P; exhibits potent therapeutic efficacy with minimal cardiac effects.Multiple Sclerosis Phase 2 Clinical.

——

——

MT-1303 hydrochloride

GPCR/G Protein

Lysophospholipid Receptor

Lysophospholipid Receptor

Inflammation/Immunology

Multiple Sclerosis

942398-84-7

413.9026

C19H31ClF3NO3

>98% (HPLC)

DMSO: ≥ 32 mg/mL

CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl

1,3-Propanediol, 2-amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years